Exec Chat: Binah.ai CEO And Founder Discusses Racial Disparities In Clinical Trials
David Maman is the CEO and founder of Binah.ai, a provider of video-based health monitoring tools powered by artificial intelligence. Maman shared with Medtech Insight his thoughts on the FDA’s recent guidance to increase racial and ethnic diversity in clinical trials.
You may also be interested in...
US Medicare has granted a new technology add-on payment (NTAP) for an innovative technology designed to treat adult spinal deformity.
Agency issued an emergency use authorization to Labcorp for its OTC that detects COVID-19, flu and respiratory syncytial virus.
Draft legislation out of the US Senate Health, Education, Labor and Pensions (HELP) Committee gives the FDA authority to regulate certain in vitro diagnostics known as laboratory developed tests.